BioBoyScout
Subscribe
Sign in
Home
White Papers
Notes
Disclosures
About
Latest
Top
Discussions
DIMER Topline: Neither Half Was a Passenger
Arrowhead reported this morning that one molecule silenced two genes in humans. The headline is a lipid drug. The result is that a question about…
Sep 15
•
BioBoyScout
3
The Outpost
Biotech clusters around Boston, South San Francisco and San Diego. Arrowhead's delivery platform traces back to Wisconsin, and the reason that mattered…
Sep 14
•
BioBoyScout
4
1
Undrilled Acreage
Three banks published on Arrowhead in one week, used different methods, and landed in the same neighborhood. Conventional valuation has no natural place…
Sep 9
•
BioBoyScout
7
1
1
Pelacarsen: The Refutation
Novartis lowered Lp(a) in 8,323 patients and failed to show fewer cardiovascular events. The drug hit its target. The hypothesis did not. That…
Sep 4
•
BioBoyScout
12
1
2
The Number Nobody Is Watching: The Case for Early Approval
Accelerated approval on a tau biomarker has never been granted. Three recent decisions show what it may take, and the answer is not the biomarker…
Sep 2
•
BioBoyScout
5
1
The Infusion Chair
Arrowhead presented a second Phase 3 result in Munich on Monday morning. Different disease, different competitor, hardly anybody in the room. The…
Sep 1
•
BioBoyScout
11
1
August 2026
Second, With the Better Drug
Arrowhead presented the full SHASTA-3 and SHASTA-4 results in Munich on Sunday. The triglyceride numbers beat the competitor's, and so does the dosing…
Aug 31
•
BioBoyScout
6
1
The Adjudicator
Arrowhead announced its ESC schedule this week. Two decisions inside that announcement were not made by Arrowhead, and they are the most informative…
Aug 25
•
BioBoyScout
8
The Other September Readout
Everyone is watching the brain. The quieter half of Arrowhead's September tests something the brain readout cannot: whether the engine can build a new…
Aug 24
•
BioBoyScout
6
2
The Jordan Premium
Why the market cannot price a drug-discovery engine, and what Arrowhead's is really worth. A guide to valuing the machine, not just the medicines it has…
Aug 17
•
BioBoyScout
5
The Keystone
The rerate case for Arrowhead: one readout this September answers four questions at once, and reprices more than one company. A framework for reading…
Aug 10
•
BioBoyScout
11
2
Arrowhead Q3: Don't Read the Quarter, Read the Setup
My quick take on today's numbers and the call. The quarter doesn't matter much, and that is the point. What matters: the biggest prize got closer, and…
Aug 4
•
BioBoyScout
3
This site requires JavaScript to run correctly. Please
turn on JavaScript
or unblock scripts
